Financial Report
1 January - 31 December
Attributable to shareholders of PolyPeptide Group AG:
|
|
|
|
|
|
|
|
|
|
kEUR |
Share capital |
Share premium |
Translation reserve |
Treasury shares |
Other capital reserves |
Retained earnings |
Total |
|
|
|
|
|
|
|
|
|
|
Balance as at 1 January 2021 |
33,000 |
2,340 |
-5,616 |
0 |
0 |
147,936 |
177,660 |
|
|
|
|
|
|
|
|
|
|
Result for the year |
|
|
|
|
|
47,258 |
47,258 |
|
Remeasurement gain / (loss) on defined benefit plans, net of tax |
|
|
|
|
|
833 |
833 |
|
Currency exchange differences |
|
|
14,901 |
|
|
|
14,901 |
|
Total comprehensive income |
0 |
0 |
14,901 |
0 |
0 |
48,091 |
62,992 |
|
|
|
|
|
|
|
|
|
|
Business restructuring |
-33,000 |
33,000 |
|
|
|
|
0 |
|
Incorporation of PolyPeptide Group AG |
273 |
|
|
|
|
|
273 |
|
Issue of new shares |
29 |
182,112 |
|
|
|
|
182,141 |
|
IPO-related costs charged to equity |
|
-4,652 |
|
|
|
|
-4,652 |
|
Purchase of own shares |
|
|
|
-5,464 |
|
|
-5,464 |
|
Share-based payment |
|
|
|
|
4,264 |
|
4,264 |
|
Transfer of own shares |
|
|
|
4,277 |
-3,316 |
|
961 |
|
Repayment by Draupnir Holding B.V. related to IPO bonus |
|
|
|
|
2,998 |
|
2,998 |
|
Total transactions with owners |
-32,698 |
210,460 |
0 |
-1,187 |
3,946 |
0 |
180,520 |
|
Balance as at 31 December 2021 |
302 |
212,800 |
9,285 |
-1,187 |
3,946 |
196,027 |
421,173 |
|
kEUR |
Share capital |
Share premium |
Translation reserve |
Treasury shares |
Other capital reserves |
Retained earnings |
Total |
|
|
|
|
|
|
|
|
|
|
Balance as at 1 January 2020 |
33,000 |
2,340 |
-2,694 |
0 |
0 |
116,770 |
149,416 |
|
|
|
|
|
|
|
|
|
|
Result for the year |
|
|
|
|
|
31,335 |
31,335 |
|
Remeasurement gain / (loss) on defined benefit plans, net of tax |
|
|
|
|
|
-169 |
-169 |
|
Currency exchange differences |
|
|
-2,922 |
|
|
|
-2,922 |
|
Total comprehensive income |
0 |
0 |
-2,922 |
0 |
0 |
31,166 |
28,244 |
|
Balance as at 31 December 2020 |
33,000 |
2,340 |
-5,616 |
0 |
0 |
147,936 |
177,660 |